A new study has found that initiating selexipag treatment within 12 months of diagnosing pulmonary arterial hypertension (PAH) reduces hospitalizations and overall healthcare costs.

The study, published in Chest, found a 24% lower rate of all-cause hospitalizations among patients started on selexipag within 12 months of their diagnosis.

“A recent post-hoc analysis of the GRIPHON trial demonstrated that initiating selexipag, an oral PPA [prostacyclin pathway agent], within 6 months of PAH diagnosis was associated with a more pronounced effect on delaying disease progression than initiating selexipag >6 months after diagnosis,” the authors wrote. “Here, the impact of initiating selexipag within 12-months of PAH diagnosis on hospitalization and healthcare costs are assessed in real-world setting.”

Continue Reading

The research team conducted a retrospective cohort study of 1090 adults from the randomized, controlled GRIPHON study who were diagnosed with PAH between October 2015 and September 2019 who also had a prescription for medication within 12 months of the diagnosis. Patients were divided into early and nonearly use of selexipag.

Read more about PAH therapies

The team assessed all-cause hospitalization rates and total annual medical costs and compared them between the groups.

The results showed that early use of selexipag was associated with a 24% decrease in all-cause hospitalization compared with those not on early selexipag, and that total medical costs per year were also lower in the early selexipag group. Furthermore, the costs of hospitalizations and outpatient visits were lower in the early selexipag group.

Selexipag is a selective prostacyclin receptor agonist that is available as an oral medication. In the GRIPHON study, using selexipag delayed disease progression and reduced the risk of morbidity or mortality compared with placebo, with a more pronounced beneficial effect on newly diagnosed patients.


Tsang Y, Kim Y, Tilney R. Impact of initiating selexipag within 12 months of pulmonary arterial hypertension diagnosis on hospitalization and health care costs. Chest. Published online October 1, 2022. doi:10.1016/j.chest.2022.08.1927